Immunologic changes to autologous transfusion after operational trauma in malignant tumor patients: neopterin and interleukin-2.
OBJECTIVE
To estimate the impact of autologous transfusion on the status of perioperative immune activation in malignant tumor patients. The Serum Neopterin and Interleukin-2 (IL-2) were measured.


METHODS
Sixty patients undergoing elective radical resection for malignant stomach tumor were enrolled in the prospective study and assigned to the following groups: (1) Group A received autologous transfusion. (2) Group H received allogeneic transfusion. The perioperative course (Before induction of anesthesia, after operation and 5 d after operation) of Neopterin and IL-2 was compared.


RESULTS
In group A, Serum Neopterin was significantly lower than baseline after operation and IL-2 had no significant changes. In group H, both Serum Neopterin and IL-2 were significantly lower than baseline after operation and 5 d after operation. Compared with group A, Serum Neopterin was significantly lower than baseline after operation and 5 d after operation and IL-2 was significantly lower than baseline 5 d after operation.


CONCLUSIONS
Autologous transfusion decreased the perioperative immune suppression in malignant stomach tumor patients.
Yan
Min
M
Department of Anesthesiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. yanminnina@hotmail.com
Chen
Gang
G
Fang
Ling-ling
LL
Liu
Zi-ming
ZM
Zhang
Xiu-lai
XL
D000328:Adult; D000368:Aged; D001804:Blood Transfusion, Autologous / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D019798:Neopterin / Q000097:blood / Q000276:immunology*; D019990:Perioperative Care / Q000009:adverse effects* / Q000379:methods; D011178:Postgastrectomy Syndromes / Q000097:blood / Q000209:etiology* / Q000276:immunology*; D013274:Stomach Neoplasms / Q000097:blood / Q000276:immunology* / Q000601:surgery*; D016896:Treatment Outcome
D007376:Interleukin-2; D019798:Neopterin